Pasar al contenido principal

ESTUDIO DEL EFECTO DEL TRATAMIENTO CON QUERCETINA Y DEL TRASPLANTE DE MICROBIOTA INTESTINAL EN MODELOS EXPERIMENTALES DE HIGADO GRASO NO ALCOHOLICO

BFU2013-48141-R

•
Nombre agencia financiadora Ministerio de Economía y Competitividad
Acrónimo agencia financiadora MINECO
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2013
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Unidad de gestión Secretaría de Estado de Educación, Formación Profesional y Universidades
Centro beneficiario UNIVERSIDAD DE LEÓN
Identificador persistente http://dx.doi.org/10.13039/501100003329

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

BULERIA. Repositorio Institucional de la Universidad de León
Publicación Artículo científico (JournalArticle)

A Network Involving Gut Microbiota, Circulating Bile Acids, and Hepatic Metabolism Genes That Protects Against Non‐Alcoholic Fatty Liver Disease

  • Petrov, Petar Dianov
  • García Mediavilla, María Victoria
  • Guzmán, Carla
  • Porras Sanabria, David
  • Nistal González, Maria Esther
  • Martínez Flórez, Susana
  • Castell, José Vicente
  • González Gallego, Javier
  • Sánchez Campos, Sonia
  • Jover Atienza, Ramiro
[EN] Scope: Gut microbiota contributes to non-alcoholic fatty liver disease (NAFLD) pathogenesis by multiple mechanisms not yet completely understood. Novel differential features between germ-free mice (GFm) transplanted with protective or non-protective cecal microbiota against NAFLD are investigated. Methods and results: Gut microbiota composition, plasma, and fecal bile acids (BAs) and liver mRNAs are quantified in GFm recipients from four donor mice differing in NAFLD severity (control diet, high-fat diet [HFD]-responder, HFD-non-responder, and quercetin-supplemented HFD). Transplanted GFm are on control or HFD for 16-weeks. Multivariate analysis shows that GFm colonized with microbiota from HFD-non-responder and quercetin supplemented-HFD donors (protected against NAFLD) clusters together, whereas GFm colonized with microbiota from control and HFD-responder mice (non-protected against NAFLD) establishes another cluster. Protected phenotype is associated with increased gut Desulfovibrio and Oscillospira, reduced gut Bacteroides and Oribacterium, lower primary and higher secondary BAs in plasma and feces, induction of hepatic BA transporters, and repression of hepatic lipogenic and BA synthesis genes. Conclusion: Protective gut microbiota associates with increased specific secondary BAs, which likely inhibit lipogenic pathways and enhance bile flow in the liver. This novel cross-talk between gut and liver, via plasma BAs, that promotes protection against NAFLD may have clinical and nutritional relevance, SI, P.D.P. and M.V.G.-M. share first authorship. S.S.-C. and R.J. share se-nior authorship. The authors thank Drs. G ́erard and Rabot, from MI-CALIS Institute (INRA), for providing germ-free mice. The authors wouldalso like to thank the Analytical Unit of Instituto de Investigaci ́on San-itaria La Fe, Valencia, for performing the bile acid profiling in plasmaand feces. This study has been funded by Instituto de Salud Carlos IIIthrough the project “PI17/01089” (cofounded by European Regional De-velopment Fund “A way to achieve Europe”) and by grants from Minis-terio de Econom ́ıa y Competitividad/Fondo Europeo de Desarrollo Re-gional (FEDER) (BFU2013-48141-R and BFU2017-87960-R) and Junta deCastilla y Le ́on/FEDER (LE063U16 and GRS1888/A/18). P.D.P. was sup-ported by Sara Borrell Postdoctoral Contract CD18/00158 from the Insti-tuto de Salud Carlos III, cofounded by the European Social Fund. D.P.was supported by a fellowship from Junta de Castilla y Le ́on cofinancedby the European Social Fund. E.N. was supported by Fundaci ́on de Inves-tigaci ́on Sanitaria of Le ́on. M.V.G.-M. was supported by CIBERehd con-tracts. CIBERehd is funded by the Instituto de Salud Carlos III, Spain
BULERIA. Repositorio Institucional de la Universidad de León
Publicación Artículo científico (JournalArticle)

Functional Interactions between Gut Microbiota Transplantation, Quercetin, and High‐Fat Diet Determine Non‐Alcoholic Fatty Liver Disease Development in Germ‐Free Mice

  • Porras Sanabria, David
  • Nistal González, Maria Esther
  • Martínez Flórez, Susana
  • Olcoz Goñi, José Luis
  • Jover Atienza, Ramiro
  • Jorquera, F.
  • González Gallego, Javier
  • García Mediavilla, María Victoria
  • Sánchez Campos, Sonia
[EN] Scope: Modulation of intestinal microbiota has emerged as a new therapeutic approach for non-alcoholic fatty liver disease (NAFLD). Herein, it is addressed whether gut microbiota modulation by quercetin and intestinal microbiota transplantation can influence NAFLD development. Methods and results: Gut microbiota donor mice are selected according to their response to high-fat diet (HFD) and quercetin in terms of obesity and NAFLD-related biomarkers. Germ-free recipients displayed metabolic phenotypic differences derived from interactions between microbiota transplanted, diets, and quercetin. Based on the evaluation of hallmark characteristics of NAFLD, it is found that gut microbiota transplantation from the HFD-non-responder donor and the HFD-fed donor with the highest response to quercetin results in a protective phenotype against HFD-induced NAFLD, in a mechanism that involves gut–liver axis alteration blockage in these receivers. Gut microbiota from the HFD-responder donor predisposed transplanted germ-free mice to NAFLD. Divergent protective and deleterious metabolic phenotypes exhibited are related to definite microbial profiles in recipients, highlighting the predominant role of Akkermansia genus in the protection from obesity-associated NAFLD development. Conclusions: The results provide scientific support for the prebiotic capacity of quercetin and the transfer of established metabolic profiles through gut microbiota transplantation as a protective strategy against the development of obesity-related NAFLD, SI, M.V.G.M. and S.S.C. share senior authorship. D.P. and E.N. made equal contribution to the study. D.P., E.N., S.M.F., M.V.G.M., and S.S.C. performed most of the experiments. J.L.O. and F.J. performed statistical analysis. R.J. and J.G.G. assisted for in vivo models. S.S.C. designed the experiments and supervised the study. All the authors wrote the manuscript. The authors thank Drs. Gérard and Rabot, from MICALIS Institute (INRA), for providing germ-free mice. This work was supported by grants from Ministerio de Economía y Competitividad and Fondo Europeo de Desarrollo Regional (FEDER) (BFU2013-48141-R, BFU2017-87960-R), Junta de Castilla y León (LE135U13, GRS 1428/A/16), Junta de Castilla y León and FEDER, (LE063U16), and IIS Hospital La Fe (2017_0092_PP). D.P. was supported by a fellowship from Junta de Castilla y León co-financed by the European Social Fund. E.N. was supported by Fundación de Investigación Sanitaria of León. M.V.G.M. was supported by CIBERehd contracts. CIBERehd is funded by the Instituto de Salud Carlos III, Spain
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

An altered fecal microbiota profile in patients with non-alcoholic fatty liver disease (NAFLD) associated with obesity

  • Nistal, Esther
  • Sáenz de Miera, Luis E.
  • Ballesteros Pomar, María
  • Sánchez-Campos, Sonia
  • García-Mediavilla, María Victoria
  • Álvarez-Cuenllas, Begoña
  • Linares, Pedro
  • Olcoz, José Luis
  • Arias-Loste, María Teresa
  • García-Lobo, Juan M.
  • Crespo, Javier
  • González-Gallego, Javier
  • Jorquera Plaza, Francisco
[Introduction]: increasing evidence suggests a role of intestinal dysbiosis in obesity and non-alcoholic fatty liver disease (NAFLD). The advances in recent years with regard to the role of the gut microbiota raise the potential utility of new therapeutic approaches based on the modification of the microbiome., [Objective]: the aim of this study was to compare the bacterial communities in obese patients with or without NAFLD to those of healthy controls. Patients and methods: the fecal microbiota composition of 20 healthy adults, 36 obese patients with NAFLD and 17 obese patients without NAFLD was determined by 16S ribosomal RNA sequencing using the Illumina MiSeq system., [Results]: the results highlighted significant differences in the phylum Firmicutes between patients with and without NAFLD, which was a determining factor of the disease and supported its possible role as a marker of NAFLD. At the genus level, the relative abundance of Blautia, Alkaliphilus, Flavobacterium and Akkermansia was reduced in obese patients, both with or without NAFLD, compared to healthy controls. Furthermore, the number of sequences from the genus Streptococcus was significantly higher in patients with NAFLD in comparison with individuals without the disease, constituting another possible marker. Comparison of bacterial communities at the genus level by a principal coordinate analysis indicated that the bacterial communities of patients with NAFLD were dispersed and did not form a group., [Conclusion]: in conclusion, these results indicate the role of intestinal dysbiosis in the development of NAFLD associated with obesity. There was a differential microbiota profile between obese patients, with and without NAFLD. Thus, supporting gut microbiota modulation as a therapeutic alternative for the prevention and treatment of NAFLD., This work was supported by grants to JGG, SSC and FJ from Ministerio de Economía y Competitividad/FEDER (BFU2013-48141-R and BFU2017-87960-R), Junta de Castilla y León (BIO/LE02/15) and Gerencia Regional de Salud de Castilla y León (GRS1428/A/16 and GRS1888/A/18). MVGM was supported by CIBERehd contracts. CIBERehd is funded by the Instituto de Salud Carlos III, Spain. EN was supported by Fundación de Investigación Sanitaria of León., Peer reviewed